BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

Core Insights - BridgeBio Pharma presented positive interim analysis results from the Phase 3 FORTIFY trial of BBP-418 for LGMD2I/R9, indicating broad efficacy across key clinical endpoints and subgroups [1][2] - The company plans to submit a New Drug Application (NDA) to the FDA in the first half of 2026, with a potential U.S. launch in late 2026 or early 2027 [1][4] - If approved, BBP-418 could be the first therapy for LGMD2I/R9 and potentially the first approved treatment for any form of limb-girdle muscular dystrophy (LGMD) [1][4] Efficacy Findings - Early separation from placebo was observed in the 100-meter timed test (100MTT), with improvements in ambulation noted as early as three months after starting BBP-418 treatment [1][3] - At 12 months, BBP-418-treated individuals completed the 100MTT approximately 31 seconds faster than those on placebo [3] - The 10-meter walk test (10MWT) showed BBP-418 participants improved by 0.13 m/s, while the placebo group declined by 0.10 m/s [3] Safety Findings - BBP-418 was generally well tolerated, with treatment-emergent adverse events (TEAEs) reported in 93.2% of BBP-418 recipients compared to 100% in the placebo group [3][6] - Serious TEAEs occurred in 5.4% of BBP-418-treated individuals versus 7.9% in the placebo group, with no treatment-related serious TEAEs reported [3][6] - The most common TEAEs in the BBP-418 group included diarrhea (39.2%), procedural pain (20.3%), and falls (18.9%) [4][6] Future Plans - BridgeBio intends to initiate clinical studies of BBP-418 for individuals under 12 years of age and in other LGMD subtypes in the near future [4] - The company is also engaging with regulatory agencies to explore expedited approval pathways for BBP-418 in Europe [4]